Standard and increased canakinumab dosing to quiet macrophage activation syndrome in children with systemic juvenile idiopathic arthritis

• Asıl Yazarlar: Mikhail M. Kostik (Yazar), Eugenia A. Isupova (Yazar), Konstantin Belozerov (Yazar), Tatyana S. Likhacheva (Yazar), Evgeny N. Suspitsin (Yazar), Rinat Raupov (Yazar), Vera V. Masalova (Yazar), Irina A. Chikova (Yazar), Margarita F. Dubko (Yazar), Olga V. Kalashnikova (Yazar), Vyacheslav G. Chasnyk (Yazar), Randy Q. Cron (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Frontiers Media S.A., 2022-07-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

ObjectiveMacrophage activation syndrome (MAS) is a life-threatening, potentially fatal condition associated with systemic juvenile idiopathic arthritis (sJIA). Interleukin-1 (IL-1) is a key cytokine in the pathogenesis of sJIA MAS. Many cases of MAS are medically refractory to traditional doses of b...